Ludwig-Maximilians-Universitat Munich - Developmental Therapeutics Review - Q1 2011

Ludwig-Maximilians-Universitat Munich – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Ludwig-Maximilians-Universitat Munich – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Ludwig-Maximilians-Universitat Munich.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ludwig-Maximilians-Universitat Munich with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of Ludwig-Maximilians-Universitat Munich’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in Ludwig-Maximilians-Universitat Munich’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Ludwig-Maximilians-Universitat Munich’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of Ludwig-Maximilians-Universitat Munich in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Ludwig-Maximilians-Universitat Munich.
- Avoid Intellectual Property Rights related issues. SHOW LESS READ MORE >

List of Tables
List of Figures
Ludwig-Maximilians-Universitat Munich Snapshot
Ludwig-Maximilians-Universitat Munich Overview
Key Information
Key Facts
Ludwig-Maximilians-Universitat Munich – Research and Development Overview
Key Therapeutic Areas
Ludwig-Maximilians-Universitat Munich – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ludwig-Maximilians-Universitat Munich – Pipeline Products Glance
Ludwig-Maximilians-Universitat Munich – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ludwig-Maximilians-Universitat Munich Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ludwig-Maximilians-Universitat Munich – Drug Profiles
5-Fluorouracil + Epirubicin + Cyclophosphamide + Docetaxel
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Epirubicin + Cyclophosphamide + Docetaxel + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
5-FU + Folinic Acid + Irinotecan + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
5-FU + Folinic Acid + Irinotecan + Cetuximab
Product Description
Mechanism of Action
R&D Progress
5-FU + folinic acid + irinotecan + cetuximab + bevacizumab
Product Description
Mechanism of Action
R&D Progress
Alpha Lipoic Acid
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Ifosfamide
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Ifosfamide + Whole-Body Hyperthermia
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + docetaxel + epirubicin hydrochloride + radiation therapy
Product Description
Mechanism of Action
R&D Progress
Deflazacort
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Docetaxel
Product Description
Mechanism of Action
R&D Progress
FEC Chemotherapy + DG Chemotherapy
Product Description
Mechanism of Action
R&D Progress
FEC Chemotherapy + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Quetiapine
Product Description
Mechanism of Action
R&D Progress
Ventavis
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Oxaliplatin + Radiation therapy
Product Description
Mechanism of Action
R&D Progress
adenosine
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Irinotecan + Cetuximab
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Oxaliplatin + Cetuximab
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Oxaliplatin + Folinic Acid + Fluorouracil
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Vinorelbine
Product Description
Mechanism of Action
R&D Progress
Navelbine + Herceptin
Product Description
Mechanism of Action
R&D Progress
Simvastatin
Product Description
Mechanism of Action
R&D Progress
SQ109 + Rifampicin
Product Description
Mechanism of Action
R&D Progress
Ludwig-Maximilians-Universitat Munich – Pipeline Analysis
Ludwig-Maximilians-Universitat Munich – Pipeline Products by Therapeutic Class
Ludwig-Maximilians-Universitat Munich - Pipeline Products By Target
Ludwig-Maximilians-Universitat Munich – Pipeline Products by Route of Administration
Ludwig-Maximilians-Universitat Munich – Pipeline Products by Molecule Type
Ludwig-Maximilians-Universitat Munich - Dormant Projects
Ludwig-Maximilians-Universitat Munich - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Levetiracetam
Sulthiame
Ludwig-Maximilians-Universitat Munich – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer